|
www.aurobindo.com |
|
|
Hyderabad, February 20, 2007 |
|
|
|
Seventh
approval from MCC South Africa |
|
|
Aurobindo Pharma Limited is
delighted to announce that it has received
another marketing authorization approval from
Medicines
Control Council (MCC) of South
Africa. The Council has approved Lisinopril
tablets in 5mg, 10mg and 20mg strengths. South
African market is highly regulated and very
important in its geographical sphere. Aurobindo
by virtue of this approval can now participate
in one of the key segments of South African
market. |
|
Lisinopril is the generic version
of Zestril marketed by Astra Zeneca.
Lisinopril Dihydrate is an
effective, long acting orally administered
ACE inhibitor. It is used often in
the management of hypertension. |
|
Lisinopril belongs to a class of
drugs that today commands a market value of 27
Mio USD in South Africa. |
|
About Aurobindo Pharma Limited: |
|
Aurobindo Pharma Limited (www.aurobindo.com),
headquartered at Hyderabad, India, manufactures
generic pharmaceuticals and active
pharmaceutical ingredients. The company’s robust
product portfolio is spread over 6 major
therapeutic/product areas encompassing
(Antibiotics, Anti-Retrovirals, CVS/ Statins/Diabetology,
CNS, Gastro/Uro/Kidney therapeutics, Anti
fungal/ allergics/respiratory)
The Company markets its products
in over 100 countries. The company has filed 77
ANDAs and 106 DMFs for the USA market, in
addition to several filings in other countries.
The company has received approvals for several
facilities from leading regulatory agencies like
US FDA, UK MHRA, WHO, Health Canada, MCC South
Africa. |
For further information,
please contact:
Investor Relations
Aurobindo Pharma Limited
Plot # 2, Maitri Vihar | Ameerpet
Hyderabad - 500 038 |India
Phone (Board): +91 40 6672 5000
Mobile 0 98486 67906
Email : ir@aurobindo.com |
|
|
|
|
|
|
|
|
|
PRESS
ROOM
